CoChat

A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies

Ossenkoppele, Gert J., Lowenberg, Bob, Zachee, Pierre, Vey, Norbert, Breems, Dimitri, Van de Loosdrecht, Arjan A., Davidson, Alan H., Wells, Graham, Needham, Lindsey, Bawden, Lindsay, Toal, Martin, Hooftman, Leon, Debnam, Phillip M. · 2013 · British Journal of Haematology
Cited by 47

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: Tefinostat (CHR‐2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDAC i). This first‐in‐human, standard 3 + 3 dose escalating trial of oral, once daily tefinostat was conducted to determine the safety, tolerability, pharmacokinetic and pharmacodynamic profile of tefinostat in relapsed/refractory haematological diseases. Eighteen patients were enrolled at doses of 20–640 mg. Plasma concentrations of tefinostat exceeded those demonstrated to give in vitro anti‐proliferative activity. Flow cytometric pharmacodynamic assays demonstrated monocyte‐targeted increases in protein acetylation, without corresponding changes in lymphocytes. Dose‐limiting toxicities (DLT s) were not observed and dose escalation was halted at 640 mg without identification of the maximum tolerated dose. Drug‐related toxicities were largely Common Toxicity Criteria for Adverse Events grade 1/2 and included nausea, anorexia, fatigue, constipation, rash and increased blood creatinine. A patient with chronic monomyelocytic leukaemia achieved a bone marrow response, with no change in peripheral monocytes. An acute myeloid leukaemia type M2 patient showed a >50% decrease in bone marrow blasts and clearance of peripheral blasts. In conclusion, tefinostat produces monocyte‐targeted HDAC i activity and is well tolerated, without the DLT s, e.g. fatigue, diarrhoea, thrombocytopenia, commonly seen with non‐targeted HDAC i. The early signs of efficacy and absence of significant toxicity warrant further evaluation of tefinostat in larger studies. (clinicaltrials.gov identifier: NCT 00820508).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.12359

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Clinical Toxicities of Histone Deacetylase Inhibitors

    Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386 · cited 1×

    “Pre-clinical and clinical studies have shown that HDACi have significant potential in the treatment of cancers of diverse origins (Tan et al, 2010).”
    Background

Show all 1 references

Cited by

See all 47

Metadata

Authors
Ossenkoppele, G. J., Lowenberg, B., Zachee, P., Vey, N., Breems, D., Van de Loosdrecht, A. A., Davidson, A. H., Wells, G., Needham, L., Bawden, L., Toal, M., Hooftman, L., & Debnam, P. M.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2013-05-07
Volume
162
Issue
2
Pages
191-201
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2163931496
Cited by
47
References
1
FWCI
1.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. https://app.cochat.ai/papers/10.1111/bjh.12359
The paper
Ossenkoppele, G. J., Lowenberg, B., Zachee, P., Vey, N., Breems, D., Van de Loosdrecht, A. A., Davidson, A. H., Wells, G., Needham, L., Bawden, L., Toal, M., Hooftman, L., & Debnam, P. M. (2013). A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. British Journal of Haematology. https://doi.org/10.1111/bjh.12359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.